KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 21.96%.

  • Regeneron Pharmaceuticals' EBITDA Margin fell 4600.0% to 21.96% in Q4 2025 from the same period last year, while for Dec 2025 it was 32.0%, marking a year-over-year increase of 4200.0%. This contributed to the annual value of 32.0% for FY2025, which is 4200.0% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported EBITDA Margin of 21.96% as of Q4 2025, which was down 4600.0% from 39.33% recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBITDA Margin registered a high of 1659.2% during Q1 2022, and its lowest value of 21.96% during Q4 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 38.91% (2025), whereas its average is 176.86%.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EBITDA Margin skyrocketed by 16156200bps in 2022, and later crashed by -16315300bps in 2023.
  • Regeneron Pharmaceuticals' EBITDA Margin (Quarter) stood at 44.29% in 2021, then surged by 2685bps to 1233.4% in 2022, then tumbled by -97bps to 36.56% in 2023, then tumbled by -39bps to 22.42% in 2024, then fell by -2bps to 21.96% in 2025.
  • Its EBITDA Margin stands at 21.96% for Q4 2025, versus 39.33% for Q3 2025 and 38.5% for Q2 2025.